SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression

Figure 1

SHMT2 is highly expressed in tumor tissues from CRC patients and associated with poor prognosis and metastasis in CRC patients. (a) QPCR detection of SHMT1 and SHMT2 expression in 5 CRC tumor tissue samples and corresponding normal mucosa. . (b) WB detection of SHMT2 expression in 7 CRC tumor tissue samples and corresponding normal mucosa. (c) Immunohistochemical analysis of SHMT2 in CRC and normal mucosa tissue samples. Representative images of (A) negative SHMT2 expression of normal mucosa tissue, (B) negative expression of SHMT2 in CRC cells, (C) moderate positive expression of SHMT2 in CRC cells, and (D) strongly positive expression of SHMT2 in CRC cells. Magnification, 100x. (d) SHMT2 expression-stratified Kaplan-Meier plots for overall survival in CRC patients. Statistical significance was determined by a log-rank test. , n = 182. SHMT1: serine hydroxymethyltransferase 1 (soluble); SHMT2: serine hydroxymethyltransferase 2 (mitochondrial); CRC: colorectal cancer; QPCR: quantitative-polymerase chain reaction; WB: western blotting.

(a)

(b)

(c)

(d)